Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Three RNAi-Related Patent Applications: Mar 29, 2007

Premium
Title: Novel Oligonucleotide Compositions and Probe Sequences Useful for Detection and Analysis of microRNAs and Their Target mRNAs
 
Number: 20070065840
 
Filed: March 23, 2006
 
Lead Inventor: Irena Naguibneva, Centre National de la Recherche Scientifique-Ligue Nationale Contre le Cancer
 
The invention, the patent application’s abstract states, “relates to ribonucleic acids and oligonucleotide probes useful for detection and analysis of microRNAs and their target mRNAs, as well as small interfering RNAs. The invention furthermore relates to oligonucleotide probes for detection and analysis of other non-coding RNAs, mRNAs, mRNA splice variants, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g. alterations associated with human disease, such as cancer.”
 

 
Title: Solution-Based Methods for RNA Expression Profiling
 
Number: 20070065844
 
Filed: June 8, 2006
 
Lead Inventor: Todd Golub, Massachusetts Institute of Technology
 
The invention “is directed to novel high-throughput, low-cost, and flexible solution-based methods for RNA expression profiling, including expression of microRNAs and mRNAs,” the patent application’s abstract states.
 

 
Title: Topical Administration Permitting Prolonged Exposure of Target Cells to Therapeutic and Prophylactic Nucleic Acids
 
Number: 20070066552
 
Filed: Jan. 20, 2006
 
Lead Inventor: Peter Clarke, Introgen Therapeutics
 
According to its abstract, the patent application claims “compositions and methods for preventing or inhibiting the growth of a hyperproliferative lesion in a subject that include a nucleic acid comprised in a solid or semi-solid formation or in a transdermal or transcutaneous delivery device. Also [claimed] are compositions of a nucleic acid capable of preventing or inhibiting the growth of a hyperproliferative lesion in a subject that include an adhesive. Compositions of a nucleic acid capable of preventing or inhibiting the growth of a hyperproliferative lesion in a subject that include a nucleic acid uptake enhancer are also disclosed” in the application, the abstract states. “Methods of preventing or inhibiting the growth of a hyperproliferative lesion in a subject that involve these therapeutic compositions and devices are also disclosed.”